Major depressive disorder trials recruiting in New York

All Major depressive disorder trials nationally

Cities in New York

Recruiting trials in New York

• A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT07115329 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · New York: Cedarhurst, New York
• A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
  NCT07592689 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · New York: New York
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
  NCT06775379 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · New York: Brooklyn, Staten Island
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
  NCT07076407 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · New York: Mount Kisco, New York
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
  NCT07276997 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: New York
• A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
  NCT06223880 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: Brooklyn, Mount Kisco, New York, Staten Island
• A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT07196501 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Glen Oaks
• Aβ Dynamics in LLMD
  NCT05004987 · Phase: Phase 4 · Ages: 60 Years and older · Sex: All (male and female) · New York: New York, Orangeburg
• Biomarker-guided rTMS for Treatment Resistant Depression
  NCT04041479 · Phase: Phase 3 · Ages: 22 Years to 65 Years · Sex: All (male and female) · New York: New York
• Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality
  NCT05925322 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 80 Years · Sex: All (male and female) · New York: New York
• DBS for TRD With the Medtronic Percept PC
  NCT05773755 · Phase: Not applicable (e.g. observational or device study) · Ages: 25 Years to 70 Years · Sex: All (male and female) · New York: New York
• Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)
  NCT07111390 · Phase: Not applicable (e.g. observational or device study) · Ages: 24 Years to 65 Years · Sex: All (male and female) · New York: New York
• Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients
  NCT05239780 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · New York: New York
• Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
  NCT06559826 · Phase: Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · New York: New York
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06966401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Cedarhurst, Mount Kisco, New York, The Bronx
• Maintenance rTMS for Depression (Maitr-De)
  NCT06938841 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · New York: New York
• NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06911112 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York, The Bronx
• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06963021 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Cedarhurst, New York
• Neural Circuit Effects of Ketamine in Depression
  NCT06213324 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: New York
• Neutralizing Interleukin (IL)-6
  NCT07493317 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · New York: New York
• Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
  NCT06592833 · Phase: Phase 2 · Ages: 21 Years to 80 Years · Sex: All (male and female) · New York: New York
• Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
  NCT05757791 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: New York
• Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
  NCT06633016 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: Brooklyn, New York, Staten Island
• Study of ALTO-300 in MDD
  NCT05922878 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · New York: Rochester, Staten Island
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
  NCT05850689 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: Brooklyn, New York
• Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06786624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Mount Kisco
• Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33
  NCT05573074 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: New York, Orangeburg
• Triage Survey for Psychiatry Research Eligibility
  NCT05800925 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: New York, The Bronx
• Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT06547489 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · New York: Cedarhurst
• tDCS: Sleep to Mood in Depression (S2M-D)
  NCT07572526 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: New York